Canada Markets closed

PFE Dec 2022 80.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
At close: 03:10PM EDT
Full screen
Loading interactive chart...
  • Reuters

    UPDATE 2-FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound

    The U.S. Food and Drug Administration (FDA) has asked Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday. The drugmaker must produce the initial results of a randomized controlled trial of a second course of the antiviral by Sep. 30 next year, the FDA told Pfizer in a letter dated Aug. 5. The directive follows reports of recurrent viral infection or symptoms, or both, after the first course, including in President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.

  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    NEW YORK, August 19, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical, at the Handelsbanken Life Science Innovation Day 2022 on Wednesday, August 24, 2022 at 4:30 p.m. CEST (10:30 a.m. EDT).

  • Zacks

    Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

    Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.